Samsung Biologics signed a contract development and manufacturing organization (CDMO) deal with Texas-based Enzolytics for two drugs, including a Covid-19 treatment candidate, the Korean biopharmaceutical company said Thursday.
Samsung Biologics, Korea's largest contract manufacturer organization (CMO) of biopharmaceuticals, is gearing up to expand its footprint in the global contract development and manufacturing organization (CDMO) market.
Prime Minister Kim Boo-kyum encouraged Samsung Biologics to take an active role in helping Korea achieve “vaccine sovereignty,” during his visit to the company's plant in Yeonsu District, Incheon, Friday.
The U.S. drugmaker Moderna pledged to expand and speed up shipments of Covid-19 vaccines after leaving Korea in the lurch this summer.
Samsung Biologics’ net profit jumped 133.6 percent in the second quarter to 121.5 billion won ($105.3 million), according to a company regulatory filing on Tuesday. It beat the market consensus of 83.8 billion won compiled by FnGuide.
Making Korea a global hub of vaccine production, one of the goals laid out by President Moon Jae-in, is very slowly becoming a reality with domestic biotech companies’ growing presence in contract manufacturing organization (CMO) market.
Samsung Biologics signed a deal with Moderna Saturday to manufacture the U.S. pharmaceutical company's Covid-19 vaccines in Korea.
Executives from major companies including Samsung Electronics, Hyundai Motor and Samsung Biologics flew to the United States to discuss semiconductors and coronavirus vaccines ahead of a summit between Korea and the U.S.
Samsung Biologics will accelerate the expansion of its contract development and manufacturing organization (CDMO) business, the pharmaceutical company said Friday during its 10th general shareholder meeting held in Songdo, Incheon.
Samsung Biologics will focus on scaling up its production and research sites for the coming decades with an aim of venturing into new drug formats like vaccines and developing new medication beyond its core biosimilar business.